MedTrace Logo

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

NCT01758458 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-04-19

No results posted yet for this study

Summary

This phase I/II trial studies the side effects and best way to give laboratory treated autologous T cells together with aldesleukin and to see how well it works in treating patients with merkel cell carcinoma that has spread from the primary site (place where it started) to other places in the body. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells to kill tumor cells. Giving cellular adoptive immunotherapy with aldesleukin may be a better treatment for metastatic merkel cell carcinoma.

Conditions

  • Recurrent Merkel Cell Carcinoma
  • Stage IV Merkel Cell Carcinoma

Interventions

BIOLOGICAL

Aldesleukin

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Recombinant Interferon Beta

Given intralesionally

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Aude Chapuis · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758458 on ClinicalTrials.gov